<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636231</url>
  </required_header>
  <id_info>
    <org_study_id>NPC201501</org_study_id>
    <nct_id>NCT02636231</nct_id>
  </id_info>
  <brief_title>Endostar for Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JiangXi Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Clinical Medicine of G.D.P.U.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Ganzhou Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Gannan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether endostar and IMRT is effective in the&#xD;
      treatment of locally recurrent nasopharyngeal carcinoma patients compared with IMRT alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Locally recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity&#xD;
      modulated-radiotherapy (IMRT), but severe late toxicities become the most common reason of&#xD;
      death in IMRT salvaged NPC patients.&#xD;
&#xD;
      The aim of this phase II randomized controlled study is to address the efficacy of concurrent&#xD;
      Endostar (Endostatins) with IMRT to reduce the occurrence of severe late toxicities compared&#xD;
      with IMRT alone for locally recurrent NPC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with grade 4-5 late adverse events as assessed by RTOG/EORTC Late Radiation Morbidity Scoring Schema</measure>
    <time_frame>From 3 months after the end of IMRT to 1 year after the end of IMRT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with severe acute toxicities as assessed by CTCAE v3.0</measure>
    <time_frame>From the beginning of IMRT to 3 months after the end of IMRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the beginning the IMRT to 3 year after the end of IMRT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.&#xD;
IMRT is to give GTV 60Gy in 27 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostatins</intervention_name>
    <description>Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.</description>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
    <other_name>Endostar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT is to give GTV 60Gy in 27 fractions.</description>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_label>IMRT and concurrent Endostar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically or clinically confirmed locally recurrent nasopharyngeal carcinoma;&#xD;
&#xD;
          2. No evidence of distant metastasis&#xD;
&#xD;
          3. More than 1 year from the end of the first course of radiotherapy&#xD;
&#xD;
          4. Male, or female not in the phase of lactating or pregnancy&#xD;
&#xD;
          5. ECOG 0-2&#xD;
&#xD;
          6. Aged 18-70 years old&#xD;
&#xD;
          7. WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb&#xD;
             ≥9g/L&#xD;
&#xD;
          8. Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of&#xD;
             upper normal limits&#xD;
&#xD;
          9. Written informed consort signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Only regionally recurrence&#xD;
&#xD;
          2. Evidence of distant metastasis&#xD;
&#xD;
          3. Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the&#xD;
             bladder, oral cavity, or cervix are all permissible) are permitted&#xD;
&#xD;
          4. Severe, active co-morbidity&#xD;
&#xD;
          5. Prior anti-tumor treatment after diagnosis of local recurrence&#xD;
&#xD;
          6. MRI was not performed 3 months after the first course of radiotherapy&#xD;
&#xD;
          7. Abnormal function of heart, brain and lungs, etc&#xD;
&#xD;
          8. Lactation or pregnancy&#xD;
&#xD;
          9. Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Han, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China: Ethics Committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Clinical Medicine of G.D.P.U.</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated GanZhou Hospital of NanChang University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Gannan Medical University</name>
      <address>
        <city>GanZhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JiangXi Province Tumor Hospital</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Han F, Zhao C, Huang SM, Lu LX, Huang Y, Deng XW, Mai WY, Teh BS, Butler EB, Lu TX. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2012 Oct;24(8):569-76. doi: 10.1016/j.clon.2011.11.010. Epub 2011 Dec 29.</citation>
    <PMID>22209574</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L. Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012 Aug;6(2):309-15. doi: 10.3892/mmr.2012.903. Epub 2012 May 4.</citation>
    <PMID>22562140</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, Chen J, Hu X, Zhou Q, Wang Y, Ma H, Bao Y, Chen M. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012;7(4):e34646. doi: 10.1371/journal.pone.0034646. Epub 2012 Apr 9.</citation>
    <PMID>22496834</PMID>
  </results_reference>
  <results_reference>
    <citation>Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004 Jun 1;64(11):3731-6.</citation>
    <PMID>15172975</PMID>
  </results_reference>
  <results_reference>
    <citation>Tian YM, Guan Y, Xiao WW, Zeng L, Liu S, Lu TX, Zhao C, Han F. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma. Head Neck. 2016 Feb;38(2):225-31. doi: 10.1002/hed.23880. Epub 2015 May 27.</citation>
    <PMID>25244494</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fei Han</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Endostar</keyword>
  <keyword>IMRT</keyword>
  <keyword>recurrent</keyword>
  <keyword>NPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

